Hepatitis A-typhoid vaccine - GlaxoSmithKline

Drug Profile

Hepatitis A-typhoid vaccine - GlaxoSmithKline

Alternative Names: Hepatyrix

Latest Information Update: 19 Jan 2001

Price : $50

At a glance

  • Originator SmithKline Beecham Biologicals
  • Developer GlaxoSmithKline Biologicals
  • Class Bacterial vaccines; Hepatitis A vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Marketed Hepatitis A; Typhoid

Most Recent Events

  • 19 Jan 2001 SmithKline Beecham has merged with Glaxo Wellcome to form GlaxoSmithKline
  • 07 Jul 1999 Launched for Typhoid in United Kingdom (IM)
  • 07 Jul 1999 Launched for Hepatitis A in United Kingdom (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top